Optimization of triaryl bis-sulfones as cannabinoid-2 receptor ligands

Mackie, 2006, Annu. Rev. Pharmacol. Toxicol., 46, 101, 10.1146/annurev.pharmtox.46.120604.141254 Hertzog, 2004, Expert. Opin. Ther. Patents, 14, 1430, 10.1517/13543776.14.10.1435 Pertwee, 2000, Exp. Opin. Invest. Drugs, 9, 1553, 10.1517/13543784.9.7.1553 Huffman, 2000, Curr. Pharm. Des., 6, 1323, 10.2174/1381612003399347 Goya, 2000, Exp. Opin. Ther. Patents, 10, 1529, 10.1517/13543776.10.10.1529 Croxford, 2005, J. Neuroimmunol., 166, 3, 10.1016/j.jneuroim.2005.04.023 Carayon, 1998, Blood, 92, 3605, 10.1182/blood.V92.10.3605 Sacerdote, 2000, J. Neuroimmunol., 109, 155, 10.1016/S0165-5728(00)00307-6 McCoy, 1999, J. Pharmacol. Exp. Ther., 289, 1620 Zurier, 1998, Arthritis Rheum., 41, 163, 10.1002/1529-0131(199801)41:1<163::AID-ART20>3.0.CO;2-9 Malfait, 2000, Proc. Natl. Acad. Sci., 97, 9561, 10.1073/pnas.160105897 Baker, 2000, Nature, 404, 84, 10.1038/35003583 Quartilho, 2003, Anesthesiology, 99, 955, 10.1097/00000542-200310000-00031 Lavey, 2005, Bioorg. Med. Chem. Lett., 15, 783, 10.1016/j.bmcl.2004.11.007 Lunn, 2006, J. Pharacol. Exp. Ther., 316, 780, 10.1124/jpet.105.093500 Gonsiorek, 2006, J. Biol. Chem., 281, 28143, 10.1074/jbc.M602364200 Shankar, 2005, Bioorg. Med. Chem. Lett., 15, 4417, 10.1016/j.bmcl.2005.07.023 Wolfe, 2000, J. Org. Chem., 65, 1158, 10.1021/jo991699y Korfmacher, 2001, Rapid Commun. Mass Spectrom., 15, 335, 10.1002/rcm.235